NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Telum Therapeutics

Telum Therapeutics

Private
SpainHealthcare & Life Scienceshttps://telumtherapeutics.com/

Last Round

Series A

Jul 1, 2026

Total Funding Raised

$25.65M

Momentum

Top 5%

of companies Caplight tracks

Company Overview

Telum Therapeutics is a biotechnology company that develops antimicrobial therapies based on engineered phage lytic proteins to treat multidrug-resistant bacterial infections.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Application

Keywords

engineered phage lytic enzymesEPLEsantimicrobial resistancedrug discoveryenzybioticsmultidrug-resistant bacteriaAI drug discoveryprotein engineeringsynthetic biologyphage therapyantibiotic alternativescomputational biologybiotech platform

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Telum Therapeutics Comps

Public and private peers based on sector, stage, and business model.

Telum Therapeutics comps — public and private peers by sector, stage, and business model
CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Telum Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series AJul 1, 2026
SeedJul 13, 2020

Key People

Founding team and executive leadership

Roberto Diez-Martinez

COO & Founder, Board Member

Founding Team

Rubén Díez

CFO & Co-Founder - BoD member

Founding Team

Subhendu Basu

CEO

Executive Team

Diana Gutiérrez Fernández

Global CSO, CTO, Head of Bioinformatics

Executive Team

Telum Therapeutics Investors

Notable investors and investment history

Telum Therapeutics investors
InvestorRounds
AMR Action FundSeries A
CDTI InnvierteSeries A, Seed
InvereadySeries A
Clave CapitalSeries A, Seed
Center for Technological Development and InnovationSeries A
Invivo PartnersSeries A, Seed
SodenaSeries A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jul 1, 2026

    $21M round led by AMR Action Fund.

  • Jun 23, 2026

    Monthly visitors increased 82% MoM.

Telum Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Telum Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Telum Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersSpain
Employee Range20
Year Founded2019
Last FundingJul 1, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.